Division of Hematology Oncology (link)

Archambeault S, Flores NJ, Yoshimi A, Kratz CP, Reising M, Fischer A, Noellke P, Locatelli F, Sedlacek P, Flotho C, Zecca M, Emanuel PD, Castleberry RP, Niemeyer CM, Bader P, Loh ML. Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood. 2008 Feb 1;111(3):1124-7. Epub 2007 Nov 13.

Balamurugan A, Lucy I, Reeve G, Mehta P, Bates JH. Incidence of female breast cancer in Arkansas: are we following the national trend?  J Ark Med Soc. 2009 Jun;105(12):283-4, 286. 

Barlogie B, Anaissie E, van RF, Haessler J, Hollmig K, Pineda-Roman M, Cottler-Fox M, Mohiuddin A, Alsayed Y, Tricot G, Bolejack V, Zangari M, Epstein J, Petty N, Steward D, Jenkins B, Gurley J, Sullivan E, Crowley J, Shaughnessy JD. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007 Jul; 138(2):176 - 185. 

Barlogie B, Anaissie E. Haessler J, van RF, Pineda-Roman M, Hollmig K, Alsayed Y, Epstein J, Shaughnessy JD, Crowley J. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008 Jul 15 113 (2): 355 - 359.   

Barlogie B, Pineda-Roman M, van RF, Haessler J, Anaissie E, Hollmig K, Alsayed Y, Waheed S, Petty N, Epstein J, Shaughnessy JD, Tricot G, Zangari M, Zeldis J, Barer S, Crowley J. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008 Oct 15 112 (8): 3115 - 3121.   

Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van RF, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006 Mar; 354(10):1021 - 1030.   

Barlogie B, Tricot G, Haessler J, van RF, Cottler-Fox M, Anaissie E, Waldron J, Pineda-Roman M, Thertulien R, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Crowley J, Sawyer J. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. Blood 2008 Jan; 111(1):94 - 100.  

Barlogie B, Tricot G, Rasmussen E, Anaissie E, van RF, Zangari M, Fassas A, Hollmig K, Pineda-Roman M, Shaughnessy J, Epstein J, Crowley J. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood 2006 Apr; 107(7):2633 - 2638.   

Barlogie B, van RF, Shaughnessy JD, Epstein J, Yaccoby S, Pineda-Roman M, Hollmig K, Alsayed Y, Hoering A, Szymonifka J, Anaissie E, Petty N, Kumar NS, Srivastava G, Jenkins B, Crowley J, Zeldis JB. Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 2008 Oct 15 112 (8): 3122 - 3125. 

Barlogie B, Zangari M, Bolejack V, Hollmig K, Anaissie E, van RF, Pineda-Roman M, Mohiuddin A, Crowley J, Tricot G. Superior 12-year survival after at least 4-year continuous remission with tandem transplantations for multiple myeloma. Clin Lymphoma Myeloma 2006 May; 6(6):469 - 474. 

Choi H, Jackson NL, Shaw DR, Emanuel PD, Liu YL, Tousson A, Meng Z, Blume SW. mrtl-A translation/localization regulatory protein encoded within the human c-myc locus and distributed throughout the endoplasmic and nucleoplasmic reticular network. J Cell Biochem 2008 Nov 1;105(4):1092-108.

Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15;15(16):5258-66. Epub 2009 Aug 11.

Divekar RD, Mehta P, El-Serag HB, Raval GG, Tancinco E, Raval P, Taddei T, Monto A, Kohlwes J. Managing Advanced Hepatocellular Carcinoma. Fed Pract. 2009;26(suppl 1):1–24B.  

Eid A, Petty M, Hutchins L, Thompson R. 'Breaking bad news': standardized patient intervention improves communication skills for hematology-oncology fellows and advanced practice nurses. J Cancer Educ 2009 24 (2): 154 - 159.

Emanuel P; Mixed Myeloproliferative and Myelodysplastic Disorders. Current Hematologic Malignancy Reports 2007 2 9‑12.

Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008 June 12(22):1335-1342.

Emanuel PD. RAS pathway mutations in juvenile myelomonocytic leukemia. Acta Haematol 2008;119(4):207-11. Epub 2008 Jun 20.

Ganz PA, Hussey MA, Moinpour CM, Unger JM, Hutchins LF, Dakhil SR, Giguere JK, Goodwin JW, Martino S, Albain KS. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.J Clin Oncol 2008 Mar 10;26(8):1223-30. Epub 2008 Jan 28.

Gentry RW, Mehta J, Safar M, Kyasa MJ, Thompson R, Hester DM, Mehta P. Disclosing prognosis when patients don’t ask. Fed Pract 2006;23(4):14-16, 33.

Gentry R, Mehta J, Hester M, Thompson R, Mehta P. When is the best time to refer to hospice? Federal Practitioner 2007; 11: 51-53.

Gerena-Lewis M, Crawford J, Bonomi P, Maddox AM, Hainsworth J, McCune DE, Shukla R, Zeigler H, Hurtubise P, Chowdhury TR, Fletcher B, Dyehouse K, Ghalie R, Jazieh AR. A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer. Am J Clin Oncol 2009 May 8 [Epub ahead of print].

Greene P, Mays G, Kim K, Hagar B, Goldsmith G, Bursac Z, Carter D, Duke K, Mehta P, Henry-Tillman R. Colorectal cancer screening in Arkansas: Implications for cancer prevention in primary care. J Ark Med Soc 2009.

Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res 2006;16(6):521-6.

Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol  2006; 24(28):e48.

Govindarajan R, Ratnasinghe L, Simmons DL, Siegel ER, Midathada MV, Kim L, Kim PJ, Owens RJ, Lang NP. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25(12):1476-81.

Govindarajan R, Young JW, Harless CL, Hutchins, LF. Barriers to clinical trials vary according to the type of trial and the institution. J Clin Oncol 2007; 25 (12):1633-4; 1634.

Guo L, Lobenhofer EK, Wang C, Shippy R, Harris SC, Zhang L, Mei N, Chen T, Herman D, Goodsaid FM, Hurban P, Phillips KL, Xu J, Deng X, Sun YA, Tong W, Dragan YP, Shi L. Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol 2006 Sep 24 (9): 1162 - 1169. 

Haessler J, Shaughnessy JD, Zhan F, Crowley J, Epstein J, van RF, Anaissie E, Pineda-Roman M, Zangari M, Hollmig K, Mohiuddin A, Alsayed Y, Hoering A, Tricot G, Barlogie B. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007 Dec; 13(23):7073 - 7079. 

Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van RF, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 2006 Sep; 108(5):1724 - 1732. 

Harrington SE, Smith TJ. The role of chemotherapy at the end of life: "when is enough, enough?". JAMA. 2008 Jun 11;299(22):2667-78.

Henry-Tillman R, Mehta P. Breaking down barriers to colorectal cancer screening. Fed Pract 2008;25(7):14, 16.

Herman D, Ong TT, Usaj G, Mathur H, Baranger HU. Level Spacings in Random Matrix Theory and Coulomb Blockade Peaks in Quantum Dots. Phys. Rev. 2007:195448.  

Hershman DL, Unger JM, Barlow WE, Hutchins LF, Martino S, Osborne CK, Livingston RB, Albain KS. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 2009 May 1 27 (13): 2157 - 2162.

Hesketh PJ, Younger J, Sanz-Altamira P, Hayden M, Bushey J, Trainor B, Krentzin M, Nowd P, Arnaoutakis K, Hesketh AM. Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer. 2008 Dec 6. [Epub ahead of print] 

Hoering A, Crowley J, Shaughnessy JD, Hollmig K, Alsayed Y, Szymonifka J, Waheed S, Nair B, van RF, Anaissie E, Barlogie B. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood. 2009 Aug 13;114(7):1299-305. Epub 2009 Jun 10.

Hutchins LF, Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak VK. Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.Cancer. 2007 Nov 15;110(10):2269-75.

Kapoor P, Singh E, Radhakrishnan P, Mehta P. Splenectomy in plasma cell dyscrasias: a review of clinical practice. Am J Hematol 2006; 81: 945-54.

Keshava-Prasad H, Hester DM, Mehta J, Mehta P. Informed consent in medical oncology. Fed Pract 2008;25(7):26, 29-31, 35.

Khatcheressian J, Harrington SB, Lyckholm LJ, Smith TJ. 'Futile care': what to do when your patient insists on chemotherapy that likely won't help. Oncology (Williston Park). 2008 Jul 22(8):881-8; discussion 893, 896, 898. Comment in Oncology (Williston Park) 2008 Oct 22(11):1206.

Kyasa MJ., Breau RL., Hanna E., Suen JY., Maddox AM. Gemcitabine and Cisplatin in Patients With Locally Advanced, Recurrent, or Metastatic Head and Neck Cancer: Results of a Phase II Trial. Journal of Applied Research 2008 Vol. 8(No. 1):43-47.

Linden HM, Haskell CM, Green SJ, Osborne CK, Sledge GW Jr, Shapiro CL, Ingle JN, Lew D, Hutchins LF, Livingston RB, Martino S. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol 2007; 25(6):656-61. 

Liu YL., Castleberry RP., Emanuel PD. PTEN deficiency is a common defect in juvenile myelomonocytic leukemia. Leuk Res 2009 May; 33(5):671 - 677.

Liu YL., Castleberry RP., Emanuel PD. Author’s response to the comments on “PTEN deficiency is a common defect in juvenile myelomonocytic leukemia.” Leuk Res 2009 Jun 4.

Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, Trebo M, Wlodarski M, Zecca M, Shannon KM, Niemeyer CM. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood. 2009 Jul 1. [Epub ahead of print]

Makhoul I, Claxton D, Rybka W. Pure B-Cell Disorders. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Hematology [Internet]. Aug 25, 2006. Available from: http://www.emedicine.com/med/topic216.htm. 

Makhoul I, Harvey H, Makhoul H, Souba W. Breast cancer. eMedicine,  eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Oncology [Internet].Sep20, 2006. http://www.emedicine.com/med/topic2808.htm. 

Makhoul I, Javeed M, Ballard J. Spur Cell Anemia. eMedicine, eMedicine Specialites: Medicine, OB/Gyn, Psychiatry, and Surgery: Hematology [Internet]. Aug 25, 2006. Available from: http://www.emedicine.com/med/topic2163.htm.

Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.J Clin Oncol. 2008 Apr 20;26(12):1965-71. Epub 2008 Mar 10.

Mansoor M, Ryan CJ, Makhoul I, Sachdeva K, Curti B. Germ Cell Tumors. eMedicine, eMedicine Specialties: Medicine, OB/Gyn, Psychiatry, and Surgery: Oncology[Internet]. July 27, 2006. http://www.emedicine.com/med/topic863.htm. 

Mehta P. Poems on Cancer Education. J Cancer Educ 2006; 21(2):108-9.

Mehta P. Chemotherapy induced neutropenia in the new millennium. Federal Practitioner 2006; 23 (supplement 2) 2-3. 

Mehta P. He didn't have a chance. J Clin Oncol 2007 Aug 1;25(22):3378-9.

Mehta P. Special Treatment: A commentary on "When Two Worlds Collide." J Clin Oncology 2007; 25: 4018-9.

Mehta P, Hester M, Safar AM, Thompson R. Ethics-in-oncology forums. J Cancer Educ 2007 Fall;22(3):159-64.

Mehta P, Nair B. TNF alpha inhibition and AML. Am J Hematol 2007 Dec 27; [Epub ahead of print]

Mehta P;Holtan SG; Knowing too much. J Cancer Educ 2008 23 (2): 133 - 134.

Mehta P, Henry-Tillman R. Obesity-related cancer: an emerging need for more education. J Cancer Educ 2008;23(4):201-3.

Mehta P, Henry-Tillman R. Guest Editorial: Colorectal cancer screening in the VA. Fed Pract 2008 July. 

Mehta P, Lyckholm L. Point/Counterpoint: Is burnout a well recognized issue among physicians? HemOncToday 2008 6:11.

Meng Z, Jackson NL, Choi H, King PH, Emanuel PD, Blume SW. Alterations in RNA-binding activities of IRES-regulatory proteins as a mechanism for physiological variability and pathological dysregulation of IGF-IR translational control in human breast tumor cells. J Cell Physiol 2008 Oct;217(1):172-83.

Midathada M, Mehta J, Govindarajan R, Safar AM, Hester DM, Kyasa MJ, Mehta P. When substance abuse interferes with cancer treatment. Federal Practitioner 2006; 23 (9): 39-51. 

Monzavi-Karbassi B, Hennings LJ, Artaud C, Liu T, Jousheghany F, Pashov A, Murali R, Hutchins LF, Kieber-Emmons T. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine 2007; 25(16):3022-31. 

Nair B, Mehta P. Reviews of “Bone Marrow and Stem Cell Transplantation” and “Renewing the Stuff of Life: Stem Cells, Ethics and Public Policy,” JAMA 2007; 298: 1571.

Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. Am J Hematol 2007 Nov;82(11):1022-4.

Nair B, Safar A, Garrison W, Sherman A, Mehta P. Smoking cessation among patients in a cancer clinic: evaluation of a novel, motivational stop-smoking pocket calendar. J Cancer Educ. 2009;24(3):210-1.

Nair B, Shaughnessy JD, Zhou Y, strid-Cartron M, Qu P, van RF, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B. Gene expression profiling of plasma cells at myeloma relapse from total therapy 2 predicts subsequent survival. Blood. 2009 Jun 25;113(26):6572-5. Epub 2009 Apr 23.

Norris LB and Mehta P.  The role of granulocyte growth factors. Federal Practitioner 2006; 23 (supplement 2) 16-25. 

O'Brien S, Berman E, Bhalla K, Copelan EA, Devetten MP, Emanuel PD, Erba HP, Greenberg PL, Moore JO, Przepiorka D, Radich JP, Schilder RJ, Shami P, Smith BD, Snyder DS, Soiffer RJ, Tallman MS, Talpaz M, Wetzler M; Chronic myelogenous leukemia. J Natl Compr Canc Netw 2007 May 5 (5): 474 ‑ 496.

Pineda-Roman M, Bolejack V, Arzoumanian V, Anaissie E, van RF, Zangari M, Walker R, Hollmig K, Shaughnessy JD, Epstein J, Krishna S, Crowley J, Barlogie B. Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease. Br J Haematol 2007 Feb; 136(3):393 - 399. 

Prasad HK, Govindarajan R. Heparin-induced skin necrosis associated with thrombocytopenia and acquired protein C and protein S deficiency. Am J Hematol 2007 Dec;82(12):1116-7.  

Prasad HK, Kaushal V, Mehta P. Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: case report and review of literature. Am J Hematol 2007 Sep;82(9):855-7.

Raval GG, Wingard JR, Mehta P. Bone Marrow Transplantation, Long-Term Effects. eMedicine, eMedicine Specialties: Pediatric: Oncology [Internet]. July 31, 2006.  http://www.emedicine.com/ped/topic2551.htm.  

Raza A;Galili N;Callander N;Ochoa L;Piro L;Emanuel P;Williams S;Burris H;Faderl S;Estrov Z;Curtin P;Larson RA;Keck JG;Jones M;Meng L;Brown GL; Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. J Hematol Oncol 2009 2 20. 

Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B, Maibach R, Castiglione-Gertsch M, Coates AS, Goldhirsch A, Gelber RD, SOFT/TEXT/PERCHE Steering Committee., International Breast Cancer Study Group. Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?. Ann Oncol 2008 Jul; 19(7):1231-41.

Safar AM, O'Sullivan P, Ray L, Hutchins L, Mehta P. Editorial clubs as a new teaching tool in postgraduate training. J Cancer Educ 2006; 21(3):163-5.

Safar AM, Spencer H, Su X, Cooney CA, Shwaiki A and Fan C-Y. Promoter hypermethylation for molecular nodal staging in non–small cell lung cancer. Arch Pathol Lab Med 2007; 131(6):936-941. 

Shaughnessy JD, Haessler J, van RF, Anaissie E, Pineda-Roman M, Cottler-Fox M, Hollmig K, Zangari M, Mohiuddin A, Alsayed Y, Grazziutti M, Epstein J, Crowley J, Barlogie B. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol 2007 Jun; 137(6):530 - 536. 

Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van RF, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007 Mar; 109(6):2276 - 2284. 

Sherman AC, Edwards D, Simonton S, Mehta P. Caregiver stress and burnout in an oncology unit. Palliat Support Care 2006 Mar;4(1):65-80.

Shi L, Jones WD, Jensen RV, Harris SC, Perkins RG, Goodsaid FM, Guo L, Croner LJ, Boysen C, Fang H, Qian F, Amur S, Bao W, Barbacioru CC, Bertholet V, Cao XM, Chu TM, Collins PJ, Fan XH, Frueh FW, Fuscoe JC, Guo X, Han J, Herman D, et al. The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics 2008 9 Suppl 9 S10.   

Shi L, Jones WD, Jensen RV, Wolfinger RD, Kawasaki ES, Herman D, Guo L, Goodsaid FM, Tong W. Reply to statistical methods and microarray data. Nat Biotechnol 2007 25 (1):26-27.   

Shi L, Jones WD, Jensen RV, Wolfinger RD, Kawasaki ES, Herman D, Guo L, Goodsaid FM, Tong W. Reply to MAQC papers over the cracks. Nat Biotechnol. 2007 (25 (1)):28-29. 

Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de LF, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006 Sep 24 (9): 1151 - 1161.   

Shippy R, Fulmer-Smentek S, Jensen RV, Jones WD, Wolber PK, Johnson CD, Pine PS, Boysen C, Guo X, Chudin E, Sun YA, Willey JC, Thierry-Mieg J, Thierry-Mieg D, Setterquist RA, Wilson M, Lucas AB, Novoradovskaya N, Papallo A, Turpaz Y, Baker SC, Warrington JA, Shi L, Herman D. Using RNA sample titrations to assess microarray platform performance and normalization techniques. Nat Biotechnol 2006 Sep 24 (9): 1123 - 1131. 

Sibley A, Maddox AM. Myelodysplasia and copper deficiency induced by denture paste. Am J Hematol. 2009 Jun 11. [Epub ahead of print]

Suva L, Griffin R, Makhoul I. Mechanisms of bone metastases of breast cancer. Endocr Relat Cancer. 2009 May 14. [Epub ahead of print] 

Swetz KM, Harrington SE, Matsuyama RK, Shanafelt TD, Lyckholm LJ. Strategies for Avoiding Burnout in Hospice and Palliative Medicine: Peer Advice for Physicians on Achieving Longevity and Fulfillment. J Palliat Med. 2009 Jul 21. [Epub ahead of print]

Unger JM, Coltman CA Jr., Drowley JJ, Hutchins LF, Martino S, Livingston RB, Macdonald JS, Blanke CD, Gandara DR, Crawford ED, Albain KS. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 2006 Jan 1;24(1):141-4. 

van RF, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, Shaughnessy JD, Zangari M, Tricot G, Mohiuddin A, Alsayed Y, Woods G, Crowley J, Barlogie B. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007 Aug; 110(3):827 - 832.   

Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD, Epstein J, van HR, Erdem E, Hoering A, Crowley J, Ferris E, Hollmig K, van RF, Zangari M, Pineda-Roman M, Mohiuddin A, Yaccoby S, Sawyer J, Angtuaco EJ. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007 Mar; 25(9):1121 - 1128.

Wang-Gillam A. Siegel E, Mayes D, Hutchins L, Zhou YH.  Anti-tumor effect of doxycycline on gioblastoma cells. J Cancer Molecules 2007 November 5;3(5)147-153. 

Wang-Gillam A, Miles DA, Hutchins LF. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates. Oncologist. 2008 Jul;13(7):821-7. Epub 2008 Jul 9.

Wang-Gillam A;Valentine J;Sherman AC; Mehta P; Experiences of Institutional Review Board (IRB) and Protocol Review and Monitoring Committee (PRMC) Rotations in Hematology/Oncology Training. J Cancer Educ 2008 23 (2): 71 - 73.

Yanni LM, Priestley JW, Schlesinger JB, Ketchum JM, Johnson BA, Harrington SE. Development of a comprehensive e-learning resource in pain management. Pain Med 2009 Jan 10 (1): 95 - 105.

Yanni LM, Weaver MF, Johnson BA, Morgan LA, Harrington SE, Ketchum JM. Management of chronic nonmalignant pain: a needs assessment in an internal medicine resident continuity clinic. J Opioid Manag 2008 Jul 4 (4): 201 - 211.

Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van RF, Zangari M, Dhodapkar M, Shaughnessy JD. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007 Feb; 109(4):1692 - 1700.   

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van RF, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD. The molecular classification of multiple myeloma. Blood 2006 Sep; 108(6):2020 - 2028.